Dr Frank P Arena, MD | |
21 Briar Ct, Cross River, NY 10518-1308 | |
(914) 763-0815 | |
(914) 763-0816 |
Full Name | Dr Frank P Arena |
---|---|
Gender | Male |
Speciality | General Practice |
Location | 21 Briar Ct, Cross River, New York |
Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
Identifier | Type | State | Issuer |
---|---|---|---|
1487856472 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
208D00000X | General Practice | 86533 (New York) | Primary |
Mailing Address | Practice Location Address |
---|---|
Dr Frank P Arena, MD 21 Briar Ct, Cross River, NY 10518-1308 Ph: (914) 763-0815 | Dr Frank P Arena, MD 21 Briar Ct, Cross River, NY 10518-1308 Ph: (914) 763-0815 |
News Archive
The administration responded to a lawsuit by a group of nuns challenging how the health law exempts them from the rule.
Established in 2007 and based in Toronto, ArcticDx has developed a test, Macula Risk-, the first of its kind and specifically designed to determine one's inherited risk for age-related macular degeneration (AMD), the most common form of acquired blindness in the developed world, affecting over 10% of individuals. ArcticDx will use the PBDF investment to undertake studies in support of a planned filing for Food and Drug Administration (FDA) approval for Macula Risk.
The School of Medicine at the University of California, Riverside, will serve as lead site for a Phase 2 clinical trial evaluating ecopipam, an investigational first-in-class drug being tested for the treatment of stuttering in adults and Tourette syndrome in pediatric patients.
A subanalysis of the phase III ALEX study has shown that alectinib 600 mg twice daily is more effective than standard of care crizotinib in Asian patients with anaplastic lymphoma kinase (ALK) positive non-small-cell lung cancer (NSCLC), researchers report at the ESMO Asia 2017 Congress.
Amgen (NASDAQ: AMGN) today announced that a second placebo-controlled Phase 3 study evaluating AMG 416 for the treatment of secondary hyperparathyroidism (SHPT) in patients with chronic kidney disease (CKD), receiving hemodialysis, met its primary and all secondary endpoints.
› Verified 8 days ago